Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial by Mateo, Joaquin, MD, Porta, Nuria, PhD, Bianchini, Diletta, MD, McGovern, Ursula, MD, Elliott, Tony, MD, Jones, Robert, Prof, Syndikus, Isabel, MD, Ralph, Christy, MD, Jain, Suneil, MD, Varughese, Mohini, FRCR, Parikh, Omi, FRCR, Crabb, Simon, MBBS, Robinson, Angus, FRCR, McLaren, Duncan, MBBS, Birtle, Alison, MD, Tanguay, Jacob, MBCHB, Miranda, Susana, BSc, Figueiredo, Ines, BSc, Seed, George, MSc, Bertan, Claudia, MSc, Flohr, Penny, BSc, Ebbs, Berni, BSc, Rescigno, Pasquale, MD, Fowler, Gemma, BSc, Ferreira, Ana, MSc, Riisnaes, Ruth, FIBMS, Pereira, Rita, BSc, Curcean, Andra, MD, Chandler, Robert, MD, Clarke, Matthew, BSc, Gurel, Bora, MD, Crespo, Mateus, MSc, Nava Rodrigues, Daniel, MD, Sandhu, Shahneen, MBBS, Espinasse, Aude, MSc, Chatfield, Peter, BSc, Tunariu, Nina, MD, Yuan, Wei, PhD, Hall, Emma, Prof, Carreira, Suzanne, PhD, de Bono, Johann S, Prof

Get full text